Exact Sciences Corporatio...
54.26
-4.25 (-7.26%)
At close: Jan 14, 2025, 3:59 PM
54.56
0.55%
After-hours Jan 14, 2025, 07:59 PM EST
undefined%
Bid 54.04
Market Cap 10.04B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.2
PE Ratio (ttm) -45.22
Forward PE n/a
Analyst Buy
Ask 56.6
Volume 3,315,564
Avg. Volume (20D) 2,431,134
Open 58.89
Previous Close 58.51
Day's Range 53.39 - 59.94
52-Week Range 40.62 - 79.62
Beta undefined

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...

Sector Healthcare
IPO Date Feb 1, 2001
Employees 6,500
Stock Exchange NASDAQ
Ticker Symbol EXAS

Analyst Forecast

According to 17 analyst ratings, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $72, which is an increase of 32.69% from the latest price.

Buy 88.24%
Hold 5.88%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Exact Sciences Corporation is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of $776.55M, reflecting a 20.04% YoY growth and earnings per share of -0.07, making a -74.07% decrease YoY.
1 month ago · Source
+9%
Exact Sciences shares are trading higher. The comp... Unlock content with Pro Subscription
2 months ago · Source
-23.48%
Exact Sciences shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.